## FORMULA (I)

$$\begin{array}{c} O \\ N \\ - \end{array}$$

$$\begin{array}{c} NH_2 \\ - \\ - \end{array}$$

$$\begin{array}{c} NH_2 \\ - \\ - \end{array}$$

$$\begin{array}{c} CHCH_3 \\ (R) \end{array}$$

· 2HCl · H<sub>2</sub>O




FIG.




FIG. 3A




FIG. 3B






FIG. 4<sup>A</sup>






FIG. 4B

Appln. Ser. To Be Assigned Treatment of Erectile Dysfunction Inventors: MILLS et al. Express Mail No. EL 894 955 880 US



Percent Relaxation from 10 μM Phenylephrine








FIG. 6




Percent Inhibition Following Treatment with Y-27632 (% of control response to PE)

IG. 7A



Percent Inhibition Following Treatment with Y-27632 (% of control response to PE)

FIG. 7E



Percent Maximum Relaxation Following Contraction to 10 μM PE





FIG. 8



**FIG. 9** 




FIG. 10A






FIG. 10B

5 4 DOCA sham 2 0.8 9.0 ICP/MAP Following Treatment with Y-27632 (50nmol)

FIG. 100








**FIG. 11A** 





**FIG. 11B**